Cited by 146PI3K/AKT/mTOR signaling in cancerCancer-related Molecular PathwaysSignaling Pathways in Disease

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

FKBP-rapamycin inhibits a cyclin-dependent kinase activity and a cyclin D1-Cdk association in early G1 of an osteosarcoma cell line

Open access

Albers, M.W., Williams, R.T., Brown, E.J., Tanaka, A, Hall, F.L., Schreiber, S.L.·1993·Journal of Biological Chemistry

Open this paper in CoChat — free account

Abstract

Upon entering a cell the natural product rapamycin, like the structurally related immunosuppressant FK506, associates with members of the FKBP family of proteins. One or more of the resulting FKBP-rapamycin complexes blocks signaling pathways emanating from some growth factor receptors. Recently, the addition of rapamycin was shown to inhibit the phosphorylation and activation of a 70-kDa ribosomal S6 protein kinase, which normally occurs minutes after the activation of certain cytokine and growth factor receptors. We now report that rapamycin can be added 4 to 6 h after the addition of serum growth factors to quiescent human osteosarcoma cells and still arrest these cells in G1. This window of action correlates with the inducible appearance of a cyclin-dependent kinase (cdk) activity, and the induction of this activity is inhibited by the addition of rapamycin. Furthermore, p36cyclin D1 associates with this cdk protein complex in lysates of untreated cells, but does not associate with this cdk protein complex in lysates of rapamycin-treated cells. Together, these studies demonstrate that FKBP-rapamycin can modulate a cyclin-dependent kinase activity and a cyclin D1-cdk association during early G1 in MG-63 human osteosarcoma cells.

Integrity signals

Registry

Crossref · 10.1016/s0021-9258(18)41602-x

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Targets for Cell Cycle Arrest by the Immunosuppressant Rapamycin in Yeast
Heitman, J., Movva, N. R., & Hall, M. N. (1991) · Science · doi:10.1126/science.1715094 · Cited by 2,055
Rapamycin-FKBP specifically blocks growth-dependent activation of and signaling by the 70 kd S6 protein kinases
Chung, J., Kuo, C. J., Crabtree, G. R., & Blenis, J. (1992) · Cell · doi:10.1016/0092-8674(92)90643-q · Cited by 1,151
Formation and Activation of a Cyclin E-cdk2 Complex During the G 1 Phase of the Human Cell Cycle
Koff, A., Giordano, A., Desai, D., Yamashita, K., Harper, J. W., Elledge, S. J., Nishimoto, T., Morgan, D. O., Franza, B. R., & Roberts, J. M. (1992) · Science · doi:10.1126/science.1388288 · Cited by 1,043
D type cyclins associate with multiple protein kinases and the DNA replication and repair factor PCNA
Xiong, Y., Zhang, H., & Beach, D. (1992) · Cell · doi:10.1016/0092-8674(92)90518-h · Cited by 1,021
Functional interactions of the retinoblastoma protein with mammalian D-type cyclins
Ewen, M. E., Sluss, H. K., Sherr, C. J., Matsushime, H., Kato, J.-Y., & Livingston, D. M. (1993) · Cell · doi:10.1016/0092-8674(93)90136-e · Cited by 1,010
A family of human cdc2‐related protein kinases.
Meyerson, M. M., Enders, G. H., Wu, C. L., Su, L., Gorka, C., Nelson, C. E., Harlow, E., & Tsai, L. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05360.x · Cited by 925
Identification and properties of an atypical catalytic subunit (p34PSK-J3/Cdk4) for mammalian D type G1 cyclins
Matsushime, H., Ewen, M. E., Strom, D. K., Kato, J.-Y., Hanks, S. K., Roussel, M. F., & Sherr, C. J. (1992) · Cell · doi:10.1016/0092-8674(92)90360-o · Cited by 897
Target of rapamycin in yeast, TOR2, is an essential phosphatidylinositol kinase homolog required for G1 progression
Kunz, J., Henríquez, R., Schneider, U., Deuter‐Reinhard, M., Movva, N. R., & Hall, M. N. (1993) · Cell · doi:10.1016/0092-8674(93)90144-f · Cited by 859
Physical interaction of the retinoblastoma protein with human D cyclins
Dowdy, S. F., Hinds, P. W., Louie, K., Reed, S. I., Arnold, A., & Weinberg, R. A. (1993) · Cell · doi:10.1016/0092-8674(93)90137-f · Cited by 746
Two distinct signal transmission pathways in T lymphocytes are inhibited by complexes formed between an immunophilin and either FK506 or rapamycin.
Bierer, B. E., Mattila, P. S., Standaert, R. F., Herzenberg, L. A., Burakoff, S. J., Crabtree, G. R., & Schreiber, S. L. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.23.9231 · Cited by 706
Self-citation

Show all 26 references

Research works printed but not linked: 5

Koltin, 1991, Mol. Cell. Biol., 11, 1718
Carbonaro-Hall, 1993, Oncogene, 8, 1649
Hall, 1993, Oncogene, 8, 1377
Williams, 1992, Oncogene, 423
Sherr, 1992, Ciba Found. Symp., 170, 209

Sorted by citations

A mammalian protein targeted by G1-arresting rapamycin–receptor complex
Brown, E. J., Albers, M. W., Bum Shin, T., ichikawa, K., Keith, C. T., Lane, W. S., & Schreiber, S. L. (1994) · Nature · doi:10.1038/369756a0 · Cited by 2,053
Self-citation
An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1
Thoreen, C. C., Kang, S. A., Chang, J. W., Liu, Q., Zhang, J., Gao, Y., Reichling, L. J., Sim, T., Sabatini, D. M., & Gray, N. S. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m900301200 · Cited by 1,803
RAFT1: A mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs
Sabatini, D. M., Erdjument-Bromage, H., Lui, M., Tempst, P., & Snyder, S. H. (1994) · Cell · doi:10.1016/0092-8674(94)90570-3 · Cited by 1,509
mTOR and cancer: insights into a complex relationship
Sabatini, D. M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1974 · Cited by 1,322
A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells.
Sekulić, A., Hudson, C. C., Homme, J. L., Yin, P., Otterness, D. M., Karnitz, L. M., & Abraham, R. T. (2000) · PubMed · Cited by 708
Control of p70 S6 kinase by kinase activity of FRAP in vivo
Brown, E. J., Beal, P. A., Keith, C. T., Chen, J., Shin, T. B., & Schreiber, S. L. (1995) · Nature · doi:10.1038/377441a0 · Cited by 705
Self-citation
Rapamune® (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression
Sehgal, S. N. (1998) · Clinical Biochemistry · doi:10.1016/s0009-9120(98)00045-9 · Cited by 660
IMMUNOPHARMACOLOGY OF RAPAMYCIN
Abraham, R. T., & Wiederrecht, G. (1996) · Annual Review of Immunology · doi:10.1146/annurev.immunol.14.1.483 · Cited by 653
Rapamycin selectively represses translation of the "polypyrimidine tract" mRNA family.
Jefferies, H. B. J., Reinhard, C., Kozma, S. C., & Thomas, G. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.10.4441 · Cited by 623
Natural products in anticancer therapy
Ab, D. R. (2001) · Current Opinion in Pharmacology · doi:10.1016/s1471-4892(01)00063-7 · Cited by 618
Activation of the PI3K/Akt pathway and chemotherapeutic resistance
West, K. A., Castillo, S. S., & Dennis, P. A. (2002) · Drug Resistance Updates · doi:10.1016/s1368-7646(02)00120-6 · Cited by 591
Identification of an 11-kDa FKBP12-rapamycin-binding domain within the 289-kDa FKBP12-rapamycin-associated protein and characterization of a critical serine residue.
Chen, J., Zheng, X. F., Brown, E. J., & Schreiber, S. L. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.11.4947 · Cited by 556
Self-citation
Marine Natural Products: A Source of Novel Anticancer Drugs
Khalifa, S. A. M., Elias, N., Farag, M. A., Chen, L., Saeed, A., Hegazy, M.-E. F., Moustafa, M. S., Abd El-Wahed, A., Al-Mousawi, S. M., Musharraf, S. G., et al. (2019) · Marine Drugs · doi:10.3390/md17090491 · Cited by 555
Fibrillar Collagen Inhibits Arterial Smooth Muscle Proliferation through Regulation of Cdk2 Inhibitors
Koyama, H., Raines, E. W., Bornfeldt, K., Roberts, J. M., & Ross, R. (1996) · Cell · doi:10.1016/s0092-8674(00)81801-2 · Cited by 520
mTOR-dependent activation of the transcription factor TIF-IA links rRNA synthesis to nutrient availabilityPreprint
Mayer, C., Zhao, J., Yuan, X., & Grummt, I. (2004) · Genes & Development · doi:10.1101/gad.285504 · Cited by 544
CDK4/6 Inhibition in Cancer: Beyond Cell Cycle Arrest
Goel, S., DeCristo, M. J., McAllister, S. S., & Zhao, J. J. (2018) · Trends in Cell Biology · doi:10.1016/j.tcb.2018.07.002 · Cited by 506
RAPT1, a mammalian homolog of yeast Tor, interacts with the FKBP12/rapamycin complex.
Chiu, M. I., Katz, H., & Berlin, V (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.26.12574 · Cited by 481
Mechanism of action of the immunosuppressant rapamycin
Dumont, F. J., & Su, Q. (1995) · Life Sciences · doi:10.1016/0024-3205(95)02233-3 · Cited by 356
Rapamycin Inhibition of the G1 to S Transition Is Mediated by Effects on Cyclin D1 mRNA and Protein Stability
Hashemolhosseini, S., Nagamine, Y., Morley, S., Desrivières, S., Merćep, L., & Ferrari, S. M. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.23.14424 · Cited by 343
The TOR pathway comes of age
Stanfel, M. N., Shamieh, L. S., Kaeberlein, M. R., & Kennedy, B. K. (2009) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2009.06.007 · Cited by 347
Rapamycin causes poorly reversible inhibition of mTOR and induces p53-independent apoptosis in human rhabdomyosarcoma cells.
Hosoi, H., Dilling, M. B., Shikata, T., Liu, L. N., Shu, L., Ashmun, R. A., Germain, G. S., Abraham, R. T., & Houghton, P. J. (1999) · PubMed · Cited by 310
Inhibitors of protein kinases and phosphatases
MacKintosh, C., & MacKintosh, R. W. (1994) · Trends in Biochemical Sciences · doi:10.1016/0968-0004(94)90127-9 · Cited by 264
Curcumin inhibits the mammalian target of rapamycin‐mediated signaling pathways in cancer cells
Beevers, C. S., Li, F., Liu, L., & Huang, S. (2006) · International Journal of Cancer · doi:10.1002/ijc.21932 · Cited by 256
Rapamycin: an anti-cancer immunosuppressant?
Law, B. K. (2005) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2004.09.009 · Cited by 252
Cell Cycle Control
Jacobs, T. W. (1995) · Annual Review of Plant Physiology and Plant Molecular Biology · doi:10.1146/annurev.pp.46.060195.001533 · Cited by 252
Immunophilins in protein folding and immunosuppression 1
Fruman, D. A., Burakoff, S. J., & Bierer, B. E. (1994) · The FASEB Journal · doi:10.1096/fasebj.8.6.7513288 · Cited by 249
Peptidylproline cis/trans isomerases
Gałat, A., & Metcalfe, S. M. (1995) · Progress in Biophysics and Molecular Biology · doi:10.1016/0079-6107(94)00009-x · Cited by 240
The 70 kDa S6 kinase: regulation of a kinase with multiple roles in mitogenic signalling
Chou, M. M., & Blenis, J. (1995) · Current Opinion in Cell Biology · doi:10.1016/0955-0674(95)80064-6 · Cited by 237
TOR Mutations Confer Rapamycin Resistance by Preventing Interaction with FKBP12-Rapamycin
Lorenz, M. C., & Heitman, J. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.46.27531 · Cited by 236
Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition.
Dudkin, L., Dilling, M. B., Cheshire, P. J., Harwood, F. C., Hollingshead, M. G., Arbuck, S. G., Travis, R., Sausville, E. A., & Houghton, P. J. (2001) · PubMed · Cited by 232
Rapamycin inhibits clonal expansion and adipogenic differentiation of 3T3-L1 cells.
Yeh, W., Bierer, B. E., & McKnight, S. L. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.24.11086 · Cited by 226
Rapamycin Resistance Tied to Defective Regulation of p27 Kip1
Luo, Y., Marx, S. O., Kiyokawa, H., Koff, A., Massagué, J., & Marks, A. R. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.12.6744 · Cited by 210
Regulation of cyclin D1 expression by mTORC1 signaling requires eukaryotic initiation factor 4E-binding protein 1
Averous, J., Fonseca, B. D., & Proud, C. G. (2008) · Oncogene · doi:10.1038/sj.onc.1210715 · Cited by 194
Understanding and controlling the cell cycle with natural products
Hung, D. T., Jamison, T. F., & Schreiber, S. L. (1996) · Chemistry & Biology · doi:10.1016/s1074-5521(96)90129-5 · Cited by 183
Self-citation
Rapamycin inhibits osteoblast proliferation and differentiation in MC3T3‐E1 cells and primary mouse bone marrow stromal cells
Singha, U. K., Jiang, Y., Yu, S., Luo, M., Lu, Y., Zhang, J., & Xiao, G. (2007) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21411 · Cited by 181
FKBP51, a novel T-cell-specific immunophilin capable of calcineurin inhibition
Baughman, G., Wiederrecht, G. J., Campbell, N. F., Martin, M. M., & Bourgeois, S. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.8.4395 · Cited by 173
The p70 S6 Kinase Integrates Nutrient and Growth Signals to Control Translational Capacity
Avruch, J., BELHAM, C. M., Weng, Q. P., Hara, K., & Yonezawa, K. (2001) · Progress in molecular and subcellular biology · doi:10.1007/978-3-642-56688-2_5 · Cited by 181
The FKBP12-Rapamycin-binding Domain Is Required for FKBP12-Rapamycin-associated Protein Kinase Activity and G1 Progression
Vilella-Bach, M., Nuzzi, P., Fang, Y., & Chen, J. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.7.4266 · Cited by 154
Defect in Multiple Cell Cycle Checkpoints in Ataxia-Telangiectasia Postirradiation
Beamish, H., Williams, R. T., Chen, P., & Lavin, M. F. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.34.20486 · Cited by 137
Self-citation
Mechanisms of resistance to rapamycins
Huang, S., & Houghton, P. J. (2001) · Drug Resistance Updates · doi:10.1054/drup.2002.0227 · Cited by 143
The Biological Role of PI3K Pathway in Lung Cancer
Sarris, E., Saif, M. W., & Syrigos, K. (2012) · Pharmaceuticals · doi:10.3390/ph5111236 · Cited by 128
Cell Replication in the Arterial Wall
Koyama, H., Olson, N. E., Dastvan, F., & Reidy, M. A. (1998) · Circulation Research · doi:10.1161/01.res.82.6.713 · Cited by 127
Mammalian anti proliferative signals and their targets
Massagué, J., & Polyák, K. (1995) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(95)90059-4 · Cited by 123
From Beach to Bedside: History of the Development of Sirolimus
Napoli, K. L., & Taylor, P. J. (2001) · Therapeutic Drug Monitoring · doi:10.1097/00007691-200110000-00012 · Cited by 118
High-dose rapamycin induces apoptosis in human cancer cells by dissociating mTOR complex 1 and suppressing phosphorylation of 4E-BP1
Yellen, P., Saqcena, M., Salloum, D., Feng, J., Preda, A., Xu, L., Rodrik-Outmezguine, V. S., & Foster, D. A. (2011) · Cell Cycle · doi:10.4161/cc.10.22.18124 · Cited by 117
In vivo antitumor effect of the mTOR inhibitor CCI‐779 and gemcitabine in xenograft models of human pancreatic cancer
Ito, D., Fujimoto, K., Mori, T., Kami, K., Koizumi, M., Toyoda, E., Kawaguchi, Y., & Doi, R. (2005) · International Journal of Cancer · doi:10.1002/ijc.21532 · Cited by 117
The Upregulation of p27Kip1 by Rapamycin Results in G1 Arrest in Exponentially Growing T-Cell Lines
Kawamata, S., Sakaida, H., Hori, T., Maeda, M., & Uchiyama, T. (1998) · Blood · doi:10.1182/blood.v91.2.561 · Cited by 117
FKBP12‐rapamycin target TOR2 is a vacuolar protein with an associated phosphatidylinositol‐4 kinase activity.
Cardenas, M. E., & Heitman, J. (1995) · The EMBO Journal · doi:10.1002/j.1460-2075.1995.tb00277.x · Cited by 117
The Potential Role of mTOR Inhibitors in Non-Small Cell Lung Cancer
Gridelli, C., Maione, P., & Rossi, A. (2008) · The Oncologist · doi:10.1634/theoncologist.2007-0171 · Cited by 106
The Somatostatin Analogue Octreotide Confers Sensitivity to Rapamycin Treatment on Pituitary Tumor Cells
Cerovac, V., Garcia, J. L. M., Rubinfeld, H., Buchfelder, M., Losa, M., Florio, T., Páez-Pereda, M., Stalla, G. K., & Theodoropoulou, M. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2951 · Cited by 107
Retroviral vector-mediated gene transfer of antisense cyclin G1 (CYCG1) inhibits proliferation of human osteogenic sarcoma cells.
Skotzko, M. J., Wu, L., Anderson, W. F., Gordon, E. M., & Hall, F. L. (1995) · PubMed · Cited by 102
Self-citation
Control of Translation by the Target of Rapamycin Proteins
Gingras, A., Raught, B., & Sonenberg, N. (2001) · Progress in molecular and subcellular biology · doi:10.1007/978-3-662-09889-9_6 · Cited by 99
4E-binding Proteins, the Suppressors of Eukaryotic Initiation Factor 4E, Are Down-regulated in Cells with Acquired or Intrinsic Resistance to Rapamycin
Dilling, M. B., Germain, G. S., Dudkin, L., Jayaraman, A. L., Zhang, X., Harwood, F. C., & Houghton, P. J. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m110782200 · Cited by 96
Inhibitors of the mammalian target of rapamycin
Dancey, J. E. (2005) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.14.3.313 · Cited by 95
Molecular characterization of a FKBP-type immunophilin from higher plants.
Luan, S., Kudla, J., Gruissem, W., & Schreiber, S. L. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.14.6964 · Cited by 91
Self-citation
Relationship of the ataxia-telangiectasia protein ATM to phosphoinositide 3-kinase
Lavin, M. F., Khana, K. K., Beamish, H., Spring, K. J., Watters, D. J., & Shiloh, Y. (1995) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(00)89083-0 · Cited by 84
The Rapamycin and FKBP12 Target (RAFT) Displays Phosphatidylinositol 4-Kinase Activity
Sabatini, D. M., Pierchala, B. A., Barrow, R. K., Schell, M. J., & Snyder, S. H. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.36.20875 · Cited by 82
Rapamycin specifically interferes with the developmental response of fission yeast to starvation
Weisman, R., Choder, M., & Koltin, Y. (1997) · Journal of Bacteriology · doi:10.1128/jb.179.20.6325-6334.1997 · Cited by 75
The Immunosuppressant Rapamycin Represses Human Immunodeficiency Virus Type 1 Replication
Roy, J., Paquette, J., Fortin, J.-F., & Tremblay, M. J. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.11.3447-3455.2002 · Cited by 76
Beta-lactams and their potential use as novel anticancer chemotherapeutics drugs
Kuhn, D. J. (2004) · Frontiers in bioscience · doi:10.2741/1420 · Cited by 74
G1 phase arrest by the phosphatidylinositol 3‐kinase inhibitor LY 294002 is correlated to up‐regulation of p27Kip1 and inhibition of G1 CDKs in choroidal melanoma cells
Casagrande, F., Bacqueville, D., Pillaire, M., Malecaze, F., Manenti, S., Breton, M., & Darbon, J.-M. (1998) · FEBS Letters · doi:10.1016/s0014-5793(98)00043-x · Cited by 74
FK506 binding protein 12 mediates sensitivity to both FK506 and rapamycin in murine mast cells
Fruman, D. A., Wood, M. A., Gjertson, C. K., Katz, H. R., Burakoff, S. J., & Bierer, B. E. (1995) · European Journal of Immunology · doi:10.1002/eji.1830250239 · Cited by 72
Rapamycin Disrupts Cyclin/Cyclin-Dependent Kinase/p21/Proliferating Cell Nuclear Antigen Complexes and Cyclin D1 Reverses Rapamycin Action by Stabilizing These Complexes
Law, M. E., Forrester, E., Chytil, A. M., Corsino, P. E., Green, G., Davis, B. J., Rowe, T. C., & Law, B. K. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-1672 · Cited by 66
Signaling by the transforming growth factor-β receptor
Yingling, J. M., Wang, X., & Bassing, C. H. (1995) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/0304-419x(95)00007-2 · Cited by 65
Potential Prospect of CDK4/6 Inhibitors in Triple-Negative Breast Cancer
Hu, Y., Gao, J., Wang, M., & Li, M. (2021) · Cancer Management and Research · doi:10.2147/cmar.s310649 · Cited by 67
Rapamycin, proliferation and geroconversion to senescence
Blagosklonny, M. V. (2018) · Cell Cycle · doi:10.1080/15384101.2018.1554781 · Cited by 65
Downregulation of Cyclin G1 Expression by Retrovirus-Mediated Antisense Gene Transfer Inhibits Vascular Smooth Muscle Cell Proliferation and Neointima Formation
Zhu, N. L., Wu, L., Liu, P. X., Gordon, E. M., Anderson, W. F., Starnes, V. A., & Hall, F. L. (1997) · Circulation · doi:10.1161/01.cir.96.2.628 · Cited by 61
Self-citation
Phosphatidylinositol 3-kinase related kinases
Abraham, R. T. (1996) · Current Opinion in Immunology · doi:10.1016/s0952-7915(96)80132-4 · Cited by 58
Results of a phase II study of sirolimus and cyclophosphamide in patients with advanced sarcoma
Schuetze, S. M., Zhao, L., Chugh, R. K., Thomas, D. G., Lucas, D. R., Metko, G., Zalupski, M. M., & Baker, L. H. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.03.022 · Cited by 53
Rapamycin Inhibits ALDH Activity, Resistance to Oxidative Stress, and Metastatic Potential in Murine Osteosarcoma Cells
Mu, X., Isaac, C. E., Schott, T., Huard, J., & Weiss, K. R. (2013) · Sarcoma · doi:10.1155/2013/480713 · Cited by 50
Cdc42 Promotes G1 Progression through p70 S6 Kinase-mediated Induction of Cyclin E Expression
Chou, M. M., Robens, J., & Gupta, M. L. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m305246200 · Cited by 51
Dihydroartemisinin inhibits the mammalian target of rapamycin-mediated signaling pathways in tumor cells
Odaka, Y., Xu, B., Luo, Y., Shen, T., Shang, C., Wu, Y., Zhou, H., & Huang, S. (2013) · Carcinogenesis · doi:10.1093/carcin/bgt277 · Cited by 50
The immunosuppressant rapamycin blocks in vitro responses to hematopoietic cytokines and inhibits recovering but not steady-state hematopoiesis in vivo
Quesniaux, V. F. J., Wehrli, S., Steiner, C. W., Joergensen, J., Schuurman, H., Herrman, P., Schreier, M., & Schüler, W. (1994) · Blood · doi:10.1182/blood.v84.5.1543.1543 · Cited by 50
Translation initiation: a critical signalling node in cancer
Robert, F., & Pelletier, J. (2009) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728220903241625 · Cited by 48
Rapamycin Selectively Blocks Interleukin-2-induced Proliferating Cell Nuclear Antigen Gene Expression in T Lymphocyte
Feuerstein, N., Huang, D., & Prystowsky, M. B. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.16.9454 · Cited by 47
Phospho-p70S6K/p85S6K and cdc2/cdk1 Are Novel Targets for Diffuse Large B-Cell Lymphoma Combination Therapy
Zhao, M. Y., Auerbach, A., D'Costa, A. M., Rapoport, A. P., Burger, A. M., Sausville, E. A., Stass, S. A., Jiang, F., Sands, A. M., Aguilera, N. S. I., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1543 · Cited by 44
LY303511 (2-Piperazinyl-8-phenyl-4 H-1-benzopyran-4-one) Acts via Phosphatidylinositol 3-Kinase-Independent Pathways to Inhibit Cell Proliferation via Mammalian Target of Rapamycin (mTOR)- and Non-mTOR-Dependent Mechanisms
Kristof, A. S., Pacheco–Rodriguez, G., Schremmer, B., & Moss, J. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.083550 · Cited by 45
Evidence for Cyclin D3 as a Novel Target of Rapamycin in Human T Lymphocytes
Hleb, M., Murphy, S., Wagner, E. F., Hanna, N. N., Sharma, N., Park, J., Li, X. C., Strom, T. B., Padbury, J. F., Tseng, Y., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m400638200 · Cited by 45
Outcome of Everolimus-Based Therapy in Hormone-Receptor-Positive Metastatic Breast Cancer Patients After Progression on Palbociclib
Dhakal, A., Thomas, R. A., Levine, E. G., Brufsky, A., Takabe, K., Hanna, M. G., Attwood, K. M., Miller, A., Khoury, T., Early, A., et al. (2020) · Breast Cancer Basic and Clinical Research · doi:10.1177/1178223420944864 · Cited by 42
Mammalian RAFT1 kinase domain provides rapamycin-sensitive TOR function in yeast.Preprint
Alarcón, C. M., Cardenas, M. E., & Heitman, J. (1996) · Genes & Development · doi:10.1101/gad.10.3.279 · Cited by 42
Cyclin D3 is down-regulated by rapamycin in HER-2-overexpressing breast cancer cells
García-Morales, P., Hernando, E., Carrasco‐García, E., Menéndez-Gutierrez, M. P., Saceda, M., & Martínez-Lacaci, I. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0363 · Cited by 38
Rapamycin Destabilizes Interleukin-3 mRNA in Autocrine Tumor Cells by a Mechanism Requiring an Intact 3′ Untranslated Region
Banholzer, R., Nair, A. P. K., Hirsch, H. H., Ming, X., & Moroni, C. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.6.3254 · Cited by 35
Induction of differentiation of human myeloid leukemia cells by immunosuppressant macrolides (rapamycin and FK506) and calcium/calmodulin-dependent kinase inhibitors
Yamamoto-Yamaguchi, Y., Okabe‐Kado, J., Kasukabe, T., & Honma, Y. (2001) · Experimental Hematology · doi:10.1016/s0301-472x(01)00626-9 · Cited by 34
p70 S6 Kinase Activation Is Not Required for Insulin-Like Growth Factor-Induced Differentiation of Rat, Mouse, or Human Skeletal Muscle Cells**This work was supported by research grants from the Direccion General de Investigacion Cientifica y Tecnica (PB95/0971), Fondo de Investigacion Sanitaria (97/2101 and 96/0863), and Generalitat de Catalunya (GRQ 94–1040 and 1995 SGR 537), Spain; a postdoctoral fellowship from Comissionat per a Universitats i Recerca, Generalitat de Catalunya (to P.K.); and a predoctoral fellowship from the Ministerio de Educacion y Cultura (to J.C.).
Canicio, J., Gallardo, E., Illa, I., Testar, X., Palacín, M., Zorzano, A., & Kaliman, P. (1998) · Endocrinology · doi:10.1210/endo.139.12.6360 · Cited by 35
Efficacy of Palbociclib Combinations in Hormone Receptor–Positive Metastatic Breast Cancer Patients After Prior Everolimus Treatment
Dhakal, A., Matthews, C. M., Levine, E. G., Salerno, K. E., Zhang, F., Takabe, K., Early, A., Edge, S. B., O'Connor, T., Khoury, T., et al. (2018) · Clinical Breast Cancer · doi:10.1016/j.clbc.2018.04.015 · Cited by 34
Rescue of Degradation‐Prone Mutants of the FK506‐Rapamycin Binding (FRB) Protein with Chemical Ligands
Stankunas, K., Bayle, J. H., Havranek, J. J., Wandless, T. J., Baker, D. A., Crabtree, G. R., & Gestwicki, J. E. (2007) · ChemBioChem · doi:10.1002/cbic.200700087 · Cited by 33
mTOR inhibition sensitizes gastric cancer to alkylating chemotherapy in vivo.
Cejka, D., Preusser, M., Fuereder, T., Sieghart, W., Werzowa, J. M., Strommer, S., & Wacheck, V. (2008) · PubMed · Cited by 30
Farnesylthiosalicylic acid blocks mammalian target of rapamycin signaling in breast cancer cells
Yue, W., Wang, J., Li, Y., Fan, P., & Santen, R. J. (2005) · International Journal of Cancer · doi:10.1002/ijc.21222 · Cited by 31
Rapamycin inhibits didemnin B‐induced apoptosis in human HL‐60 cells: Evidence for the possible involvement of FK506‐binding protein 25
Johnson, K. L., & Lawen, A. (1999) · Immunology and Cell Biology · doi:10.1046/j.1440-1711.1999.00821.x · Cited by 30
Growth inhibitory effects of FK506 and cyclosporin A independent of inhibition of calcineurin
Richter, A., Davies, D. E., & Alexander, P. M. (1995) · Biochemical Pharmacology · doi:10.1016/0006-2952(94)00423-j · Cited by 30
Negative Growth Regulation of SK-N-MC Cells by bFGF Defines a Growth Factor-sensitive Point in G2
Smits, V. A. J., van Peer, M. A., Essers, M. A. G., Klompmaker, R., Rijksen, G., & Medema, R. H. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m001764200 · Cited by 30
Preclinical results of sirolimus treatment in transplant models
Stepkowski, S. M. (2003) · Transplantation Proceedings · doi:10.1016/s0041-1345(03)00222-7 · Cited by 28
Estrogen and rapamycin effects on cell cycle progression in T47D breast cancer cells
Pang, H., & Faber, L. E. (2001) · Breast Cancer Research and Treatment · doi:10.1023/a:1012570204923 · Cited by 26
A first-in-class CDK4 inhibitor demonstrates in vitro, ex-vivo and in vivo efficacy against ovarian cancer
Mekonnen, L. B., Tadesse, S., Lenjisa, J. L., Yu, M., Noll, B. D., Heinemann, G. K., Lokman, N. A., Ricciardelli, C., Oehler, M. K., Beck, A. R., et al. (2020) · Gynecologic Oncology · doi:10.1016/j.ygyno.2020.09.012 · Cited by 25
Sirolimus-based immunosuppression with reduce dose cyclosporine or tacrolimus after renal transplantation
Formica, R. N., Lorber, K. M., Friedman, A. L., BIA, M. J., Lakkis, F. G., Smith, J. D., & Lorber, M. I. (2003) · Transplantation Proceedings · doi:10.1016/s0041-1345(03)00216-1 · Cited by 23
Immunosuppressive Drugs in HIV Disease
Argyropoulos, C., & Mouzaki, Α. (2006) · Current Topics in Medicinal Chemistry · doi:10.2174/156802606778194271 · Cited by 23
Rapamycin: Biological and therapeutic effects, binding by immunophilins and molecular targets of action
Wood, M. A., & Bierer, B. E. (1994) · Perspectives in Drug Discovery and Design · doi:10.1007/bf02171742 · Cited by 21
Role of NF-kappaB in the control of apoptotic and proliferative responses in IL-2-responsive T cells
Martínez‐A, C. (1997) · Frontiers in bioscience · doi:10.2741/a174 · Cited by 20
Effects of immunosuppressive peptidyl-prolyl cis-trans isomerase (PPIase) inhibitors, cyclosporin A, FK506, ascomycin and rapamycin, on hair growth initiation in mouse: immunosuppression is not required for new hair growth
Iwabuchi, T. (1995) · Journal of Dermatological Science · doi:10.1016/0923-1811(94)00351-e · Cited by 20
Rapamycin causes activation of protein phosphatase-2A1 and nuclear translocation of PCNA in CD4+ T cells
Morrow, P. W., Tung, H. Y. L., & Hemmings, H. C. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.08.147 · Cited by 19

Authors: Albers, M. W., Williams, R. T., Brown, E. J., Tanaka, A., Hall, F. L., & Schreiber, S. L.
Affiliations: Harvard University (US)
ORCID: Albers, M.W.
Williams, R.T.
Brown, E.J.
Schreiber, S.L.
Venue: Journal of Biological Chemistry
Publisher: Elsevier BV
Published: 1993-10
Volume: 268
Issue: 30
Pages: 22825-22829
ISSN: 0021-9258 (ISSN-L)
DOI: 10.1016/s0021-9258(18)41602-x
OpenAlex: W1485463834
Cited by: 145
References: 26
Citations by year: 2025: 1 · 2024: 1 · 2023: 2 · 2022: 1 · 2021: 2 · 2020: 3 · 2019: 1 · 2018: 3 · 2015: 5 · 2014: 1 · 2013: 3 · 2012: 3
FWCI: 5.41
Type: journal article
Language: en
Open access: hybrid
doi.org
Licence: cc-by
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
creativecommons.org/licenses/by/4.0/ (vor, 9875 d)
Locations: Journal of Biological Chemistry (publishedVersion, cc-by)
PubMed (publishedVersion)
Funders: National Institute of General Medical Sciences (GM38627)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Signaling Pathways in Disease
Keywords: rapamycin, cyclin-dependent kinases, cyclin D1, G1 cell cycle arrest, osteosarcoma, MG-63 cells, cell cycle regulation, FK506
MeSH terms: Carrier Proteins, Heat-Shock Proteins, Protamine Kinase, Humans, Immunosuppressive Agents, Polyenes, Protein Binding, Osteosarcoma, Tumor Cells, Cultured, G1 Phase, S Phase, Cyclins, Protein Serine-Threonine Kinases, Cyclin-Dependent Kinases, Sirolimus, Tacrolimus Binding Proteins, CDC2-CDC28 Kinases, Protein Kinase Inhibitors, Cyclin-Dependent Kinase 2

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

FKBP-rapamycin inhibits a cyclin-dependent kinase activity and a cyclin D1-Cdk association in early G1 of an osteosarcoma cell line

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks